Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt 2.09
FGEN's Cash to Debt is ranked higher than
60% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. FGEN: 2.09 )
FGEN' s 10-Year Cash to Debt Range
Min: 1.27   Max: No Debt
Current: 2.09

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -21.45
FGEN's Operating margin (%) is ranked higher than
79% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. FGEN: -21.45 )
FGEN' s 10-Year Operating margin (%) Range
Min: -41.29   Max: -7.78
Current: -21.45

-41.29
-7.78
Net-margin (%) -27.75
FGEN's Net-margin (%) is ranked higher than
78% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. FGEN: -27.75 )
FGEN' s 10-Year Net-margin (%) Range
Min: -49.4   Max: -14.63
Current: -27.75

-49.4
-14.63
ROA (%) -13.32
FGEN's ROA (%) is ranked higher than
79% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. FGEN: -13.32 )
FGEN' s 10-Year ROA (%) Range
Min: -5.31   Max: -5.31
Current: -13.32

ROC (Joel Greenblatt) (%) -26.37
FGEN's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. FGEN: -26.37 )
FGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12.24   Max: -12.24
Current: -26.37

» FGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with FGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 10.10
FGEN's P/S is ranked higher than
82% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. FGEN: 10.10 )
FGEN' s 10-Year P/S Range
Min: 0   Max: 10.9
Current: 10.1

0
10.9
Current Ratio 3.75
FGEN's Current Ratio is ranked higher than
69% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. FGEN: 3.75 )
FGEN' s 10-Year Current Ratio Range
Min: 3.75   Max: 4.51
Current: 3.75

3.75
4.51
Quick Ratio 3.75
FGEN's Quick Ratio is ranked higher than
70% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. FGEN: 3.75 )
FGEN' s 10-Year Quick Ratio Range
Min: 3.75   Max: 4.51
Current: 3.75

3.75
4.51

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:1FG.Germany,
FibroGen Inc was incorporated in 1993. It is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The Company's focus in the areas of fibrosis and hypoxia-inducible factor biology has generated multiple programs targeting various therapeutic areas. Its advanced product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases ("HIF-PHs"), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). FG-3019 is the Company's monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer and liver fibrosis. The Company faces competition from multiple other pharmaceutical and biotechnology companies, many of which have greater financial, technical and human resources and experience in product development, manufacturing and marketing. Its trademarks include "FibroGen".

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK